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Summary
Background—Intimate partner violence (IPV) is associated with HIV infection. We aimed to 
assess whether provision of a combination of IPV prevention and HIV services would reduce IPV 
and HIV incidence in individuals enrolled in the Rakai Community Cohort Study (RCCS), Rakai, 
Uganda.
Methods—We used pre-existing clusters of communities randomised as part of a previous family 
planning trial in this cohort. Four intervention group clusters from the previous trial were provided 
standard of care HIV services plus a community-level mobilisation intervention to change 
attitudes, social norms, and behaviours related to IPV, and a screening and brief intervention to 
promote safe HIV disclosure and risk reduction in women seeking HIV counselling and testing 
services (the Safe Homes and Respect for Everyone [SHARE] Project). Seven control group 
clusters (including two intervention groups from the original trial) received only standard of care 
HIV services. Investigators for the RCCS did a baseline survey between February, 2005, and June, 
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2006, and two follow-up surveys between August, 2006, and April, 2008, and June, 2008, and 
December, 2009. Our primary endpoints were self-reported experience and perpetration of past 
year IPV (emotional, physical, and sexual) and laboratory-based diagnosis of HIV incidence in the 
study population. We used Poisson multivariable regression to estimate adjusted prevalence risk 
ratios (aPRR) of IPV, and adjusted incidence rate ratios (aIRR) of HIV acquisition. This study was 
registered with ClinicalTrials.gov, number NCT02050763.
Findings—Between Feb 15, 2005, and June 30, 2006, we enrolled 11 448 individuals aged 15–
49 years. 5337 individuals (in four intervention clusters) were allocated into the SHARE plus HIV 
services group and 6111 individuals (in seven control clusters) were allocated into the HIV 
services only group. Compared with control groups, individuals in the SHARE intervention 
groups had fewer self-reports of past-year physical IPV (346 [16%] of 2127 responders in control 
groups vs 217 [12%] of 1812 responders in intervention groups; aPRR 0·79, 95% CI 0·67–0·92) 
and sexual IPV (261 [13%] of 2038 vs 167 [10%] of 1737; 0·80, 0·67–0·97). Incidence of 
emotional IPV did not differ (409 [20%] of 2039 vs 311 [18%] of 1737; 0·91, 0·79–1·04). SHARE 
had no effect on male-reported IPV perpetration. At follow-up 2 (after about 35 months) the 
intervention was associated with a reduction in HIV incidence (1·15 cases per 100 person-years in 
control vs 0·87 cases per 100 person-years in intervention group; aIRR 0·67, 95% CI 0·46–0·97, 
p=0·0362).
Interpretation—SHARE could reduce some forms of IPV towards women and overall HIV 
incidence, possibly through a reduction in forced sex and increased disclosure of HIV results. 
Findings from this study should inform future work toward HIV prevention, treatment, and care, 
and SHARE's ecological approach could be adopted, at least partly, as a standard of care for other 
HIV programmes in sub-Saharan Africa.
Funding—Bill & Melinda Gates Foundation, US National Institutes of Health, WHO, President's 
Emergency Plan for AIDS Relief, Fogarty International Center.
Introduction
The relation between intimate partner violence (IPV), HIV, and other sexually transmitted 
infections1–3 is bidirectional.2,4 Several pathways might explain the links between IPV and 
HIV infection. Forced sex might increase risk of direct transmission of HIV.1,3,5 Gender 
inequalities are key drivers of both IPV and HIV, and they mediate the relation between 
abuse and HIV transmission.1–3,5 Social norms that give men power over women increase 
the risk of violence against women and reduce women and girls’ ability to negotiate safe and 
consensual sex and seek protection from abuse.1,5 In addition, women who experience IPV 
and men who perpetrate IPV have a clustering of factors that increase their risk of HIV 
acquisition. Compared with women who are not exposed to abuse, those who have 
experienced lifetime IPV are more likely to report concurrent sex partners, problematic 
alcohol and substance use, transactional sex, and low or inconsistent condom use.1,5,6–8 
Norms related to masculinity often encourage men to practise more risky sex. Evidence 
suggests that male perpetrators of abuse are more likely to be infected with HIV or other 
sexually transmitted infections, engage the services of female sex workers, perpetrate non-
IPV sexual assault, and (like women who have been abused) report concurrent sex partners, 
problematic alcohol and substance use, and low or inconsistent condom use.1,8–10 HIV-
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positive status and disclosure might increase risk of IPV, and fear of violence can prevent 
women from learning and sharing their HIV status and from accessing treatment.4,5,11
Several IPV and HIV prevention studies have been done in sub-Saharan Africa—the region 
most affected by HIV/ AIDS and with some of the highest rates of IPV.12,13 However, no 
intervention has successfully reduced both IPV and HIV.14 Two cluster-randomised trials in 
South Africa, where IPV has been found to increase risk of HIV infection,15 assessed the 
effect of interventions that target gender norms and gender-based violence on HIV 
incidence. The Stepping Stones intervention was associated with a 33% reduction in 
incidence of herpes simplex virus type 2, reduced violence perpetration, and lower 
frequency of some risky behaviours, but did not affect HIV incidence.16 The Intervention 
with Microfinance for AIDS and Gender Equity (IMAGE) study reduced IPV incidence by 
55%, increased HIV testing uptake, and reduced HIV risk behaviours in young women,17 
but did not affect the rate of unprotected sex with non-spousal partners or HIV incidence.18 
Most recently, the SASA! study assessed the community-level effect of a gender-focused 
structured IPV and HIV prevention intervention in urban Uganda. Exposure to SASA! was 
associated with significant reductions in social acceptability of IPV in women and sexual 
concurrency in men. The programme was associated with decreases in physical and sexual 
IPV in women, but these reductions were not significant and the trial did not report an HIV 
outcome.19 Although these findings suggest that integrated gender equality and HIV training 
interventions offer potential synergies, they show the need for innovative strategies to 
reduce both HIV incidence and IPV.
The Safe Homes and Respect for Everyone (SHARE) Project aimed to reduce physical and 
sexual IPV and HIV incidence. SHARE uses two main approaches: community-based 
mobilisation to change attitudes and social norms that contribute to IPV and HIV risk, and a 
screening and brief intervention to reduce HIV-disclosure-related violence and sexual risk in 
women seeking HIV counselling and testing (figure 1). We aimed to assess the effect on 
past-year IPV against women, HIV incidence, and certain sexual risk behaviours of adding 
SHARE into ongoing HIV treatment and prevention activities of the Rakai Health Sciences 
Programme (RHSP).
Methods
Study design and participants
We did this comparative study in Rakai, Uganda, where IPV has been associated with HIV 
incidence.20 Rakai is a traditionally patriarchal society,21 with high HIV prevalence (12%) 
and incidence (1·2 per 100 person-years)22 and relatively high rates of IPV against women 
(29% in the past year).20 The study was nested in the Rakai Community Cohort Study 
(RCCS), described in detail elsewhere.23 RCCS is an open, community-based cohort study 
that takes a census, interviews, and serological surveys every 12–18 months in about 50 
communities that are aggregated into 11 study clusters—originally selected to be relatively 
homogeneous.24 The 50 RCCS communities represent 7% of the 720 communities in the 
Rakai district. The 11 clusters are made up of two to eight communities each and the mean 
number of households per cluster is 809.22 Before the RCCS survey, investigators do a 
census in all residents (about 28 000 individuals) in roughly 9000 households. The 
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investigators generate lists of eligible RCCS participants (ie, resident individuals aged 15–
49 years) and contact each of the individuals and ask for their consent to enrol in RCCS. 
Surveys are done in person in the local language of Luganda with structured questionnaires 
to obtain sociodemographic, behavioural, health, and care-seeking data. Sexual network 
information is obtained for up to four partners in the previous year. About 90% of eligible 
participants have consented to an interview at each survey.22,23 Blood samples are taken for 
HIV detection. About 98% of participants provide a sample for HIV testing, and are offered 
free HIV counselling and testing and risk reduction education; about 80% request their 
results and counselling.25 Those individuals who test positive are referred for care and 
treatment,25,26 including with HAART.
Our inclusion criteria were individuals aged 15–49 years who completed an RCCS interview 
and provided blood for HIV testing at baseline (Feb 15, 2005, to June 30, 2006) and at two 
follow-up visits in Aug 30, 2006, to April 24, 2008, and June 6, 2008, to Dec 7, 2009. The 
baseline survey was done before the intervention was given, and follow-up appointments 
were staggered so that each intervention cluster had roughly the same duration of exposure 
to the SHARE intervention. The first follow-up began about 16 months after the baseline 
and spanned the intervention scale-up and full implementation phases. The final follow-up 
began about 35 months after baseline. The SHARE intervention was planned to last about 4 
years, 1 year for each phase (after the community assessment): raising awareness, building 
networks, integrating action, and consolidating efforts.
Surveys were done in private by same-sex interviewers who were trained by certified Rakai 
Health Science Program ethics and clinical practice trainers in research ethics and good 
clinical practice. All interviewers were trained using WHO's guidelines for safe and ethical 
research on domestic violence,27 including IPV sensitisation, and how to minimise possible 
distress related to research on violence or sensitive topics. All women who reported IPV and 
requested assistance were actively referred to an RHSP counsellor trained to provide basic 
psychosocial support and risk reduction skills to victims. No services were made available to 
perpetrators of violence. The study was approved by the Western Institutional Review Board 
(Olympia, WA, USA), WHO's Ethics Review Committee, the Uganda Virus Research 
Institute's Scientific and Ethics Committee, and the Ugandan National Council of Science 
and Technology. All individuals gave written consent.
Cluster selection
Our study was built on a cluster-randomised trial done between April 6, 1999, and Aug 1, 
2003, to assess the effect of enhanced family planning outreach in Rakai.28 In that trial, five 
clusters were randomly assigned to receive standard family planning services (control) and 
six clusters were randomly assigned to receive a family planning intervention. We used 
these clusters in our trial. Because of funding limitations for our trial, only four intervention 
clusters were randomly chosen (with a computer-generated randomisation programme) from 
the original six family planning intervention clusters to take advantage of existing 
infrastructure for community health workers. All five control clusters from the original 
family planning study plus the remaining two family planning intervention clusters were 
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included in the seven control clusters for our trial. Investigators were not masked to study 
group assignment.
Procedures
We offered all individuals (control and intervention clusters) routine HIV prevention and 
treatment services, including free HIV testing, pretest and post-test counselling through 
community-based counsellors, and referral for care25 (panel 1). Participants in the 
intervention group were exposed to the SHARE violence-reduction intervention and 
screening and a brief intervention to reduce IPV related to HIV disclosure and risk 
behaviours in women seeking HIV counselling and testing. SHARE29 is an ecological 
framework to intervene against drivers of IPV and HIV transmission at the individual, 
relationship, and societal levels (figure 1). SHARE was based on the stages of change 
theory,30 which is most commonly used at the individual-level but adapted for use in Rakai 
at the community-level by use of the Raising Voices Resource Guide for Organizations in 
East and Southern Africa.31 SHARE involved five distinct phases and used five main 
strategies (panel 2).29
SHARE staff included three women and two men with tertiary education, training in HIV 
and psychosocial counselling, and fluency in English and Luganda language, who received 4 
weeks of training on IPV awareness and prevention, provision of violence-related support, 
and ethical protection of participants. SHARE also appointed and trained 40 community 
volunteers and 12 community counselling aides to work with core SHARE staff (appendix). 
Additionally, SHARE provided focused programmes for men, boys, and young people and 
integrated violence prevention into RHSP's existing HIV counselling and testing and 
HAART programmes (appendix).
Outcomes
Our primary endpoints were self-reported experience and perpetration of past-year IPV 
(physical, emotional, and sexual) and laboratory-based diagnosis of HIV incidence in the 
study population. Sexual IPV was defined as penetrative and non-penetrative sex, and other 
unwanted sexual acts. Abused women commonly experience more than one type of violence 
in Rakai,20 but we measured physical and sexual IPV separately to assess whether SHARE 
had a differential effect on these two outcomes. Our secondary endpoints were forced sex 
(defined as unwanted, physically forced penetrative sex) and HIV risk behaviour and 
disclosure (respondent's and primary partner's) in the last year of the intervention. We used 
an adaptation of the conflict tactics scales32 to measure each type of IPV (appendix). HIV 
risk behaviours were total number of sex partners, number of non-marital sex partners, 
alcohol use with last sex, and condom use, and disclosure of their HIV status in the past year 
(appendix).
HIV status was established from venous blood samples with two enzyme immunoassays 
(Vironostika HV-1 [Organon Teknika, Charlotte, NC, USA] and Cambridge Biotech 
[Worcester, MA, USA]), with Western blot (bioMérieux VITEK, St Louis, MO, USA) 
confirmation of discordant enzyme immunoassay results and all seroconversions. We 
analysed HIV incidence data during the SHARE trial to assess intervention efficacy before 
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the SHARE baseline (2004–05), pre-baseline similarity between study groups, and after the 
trial ended (2010–11) to assess postintervention sustainability of any effects on HIV 
incidence.
We also obtained data for social and demographic characteristics, HAART use, and male 
circumcision. The SHARE trial coincided with the introduction of HAART in June, 2004, 
by the Government of Uganda, and the last year of follow-up of a male circumcision for 
HIV prevention trial33 (stopped in December, 2006) and provision of circumcision services 
thereafter. Circumcision status was assessed by questions asking men, “are you 
circumcised?” and women were asked “is/ was your husband/recent sexual partner 
circumcised?” Female reported circumcision status of male partners has been validated in 
this population.34 HAART uptake in both groups of the trial was measured at baseline and 
follow-up with a combination of RHSP HAART clinic data and self-reported data from the 
RCCS survey.
Statistical analysis
We postulated that exposure to SHARE would lead to a minimum 10% relative reduction of 
each type of violence in the intervention group, assuming an initial physical IPV prevalence 
of about 20% and sexual IPV prevalence of about 14·5%. Because the study was nested 
within the RCCS, the effective sample size was established by enrolment into the cohort. 
For IPV outcomes, the study was powered on the basis of an approximate intervention group 
population of about 3500 individuals and a control population of roughly 11 100 people, 
giving the study 80% power to detect the hypothesised IPV reductions (two sided α=0·05). 
For the HIV incidence outcome (about 1·2 per 100 person-years), we expected about 4753 
person-years of exposure in the intervention group and about 16 969 person-years of 
exposure in the control group, and estimated 80% power (two sided α=0·05) to detect 36% 
lower HIV incidence in the intervention group compared with the control group. After 
selection of intervention clusters, sample sizes were higher for the intervention groups and 
lower for the control groups than we had initially anticipated, which had little effect on the 
power of the study.
Social and demographic characteristics, circumcision status, IPV, risk behaviours, HIV 
prevalence, and HAART use were measured at baseline to assess comparability between 
study groups. Baseline differences between groups were estimated using Pearson's χ2 and 
Fisher's exact tests for differences in proportions, and t-tests and Wilcoxon rank-sum tests 
for continuous variables. These outcomes and HIV incidence were assessed at follow-up to 
show differences between study groups with an intention-to-treat approach in which all 
eligible participants with complete data were included in the analysis by study group, 
irrespective of crossovers or direct exposure to SHARE activities. Differences in loss-to-
follow-up between the two groups were assessed by χ2 tests. We established study retention 
on the basis of the number of participants interviewed at either of the two follow-up visits. 
We used two-tailed p values (p<0·05) for statistical inference.
We analysed all outcomes separately for men and women and for the first and second 
follow-up visits. Our analysis included respondents who attended both the first and second 
follow-up visits plus respondents who were not available in follow-up 1 but were then 
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available in follow-up 2. We accounted for the cluster effect by fitting a random-intercept 
model at the cluster level to test for potential within-cluster correlation. We analysed IPV 
and secondary HIV risk behaviour outcomes as dichotomous variables. In view of the low 
correlation within clusters and difficulty of verification of the random effects assumptions 
because of the small number of clusters (n=11), we fit generalised linear models for the 
main analysis. We used a modified Poisson multivariate regression that combines a log 
Poisson regression model with number of people as the offset, and robust variance 
estimation, allowing for an approximation to the log binomial model to estimate adjusted 
prevalence risk ratios (aPRRs) for the IPV and HIV risk behaviour outcomes.35 We fitted a 
generalised linear model using a log link with the observed population as an offset and an 
assumed underlying Poisson distribution.
For analysis of HIV incidence, we calculated person-years of exposure from baseline to the 
last negative HIV result when the person remained negative, or to the midpoint of the 
interval between the last negative and first positive tests for seroconverters. HIV incidence 
was estimated per 100 person-years. We used Poisson multivariate regression models with 
robust variance estimation to estimate the adjusted incidence rate ratios (aIRR) of HIV 
acquisition between intervention to control groups. Our analysis was preplanned and did not 
adjust for multiple comparisons, but we do account for them in the interpretation.36 We used 
Stata/SE version 12 for data analysis. This trial is registered with ClinicalTrials.gov, number 
NCT02050763.
Role of the funding source
The funders had no role in study design, data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full access to all the data and had final 
responsibility for the decision to submit for publication.
Results
Between Jan 17, 2005, and May 24, 2006, 21 636 individuals from 11 clusters were assessed 
for eligibility by the RCCS census team. We enrolled 11 448 men and women aged 15–49 
years: 6111 in the control group clusters and 5337 in the intervention group clusters (figure 
2). 8565 (75%) attended either round of follow-up (4499 [74%] in the control vs 4068 [76%] 
in the intervention; p=0·0012), consistent with average RCCS follow-up rates of about 75% 
between successive visits.22,23 Across the entire trial, 7842 (69%) participants were assessed 
at follow-up 1 and 6526 (57%) participants at follow-up 2. Cumulative retention rates (ie, at 
follow-up 2) were higher in the control group (3564 [58%]) than in the intervention group 
(2962 [56%]; p=0·0031), and in women (3939 [59%]) than in men (2587 [55%]; p=0·0001). 
Because of the open nature of the cohort, loss to follow-up was mainly because participants 
could not be located. The study lasted 4 years and 7 months.
Baseline characteristics of the two study groups were broadly similar (table 1). There were 
more younger (age 15–19 years) and older (age 35 years and older) individuals in the 
intervention group than in the control group, and control group participants had higher levels 
of secondary (or more) education than had the intervention group. Physical and sexual IPV 
in women, forced sex, and HIV results disclosure were more common in the control group 
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than in the intervention group at baseline. Baseline HIV prevalence was higher in the control 
(12%) than in the intervention group (9%) for both women and men (table 1).
Table 2 shows IPV outcomes by group. The proportions of women who experienced 
physical IPV, sexual IPV, and forced sex were significantly lower in the SHARE 
intervention group at the second follow-up than in the control group after adjustment for 
baseline IPV, age, education, and marital status (table 2). The intervention did not 
significantly reduce women's experiences of emotional IPV (table 2). Men's reports of 
emotional and physical IPV perpetration decreased over the course of the trial in both 
groups, but reported final IPV rates at follow-up did not differ significantly (table 2).
Women's reports of their own disclosure of HIV status and their partner's disclosure of his 
HIV status were higher in the intervention than in the control group at second follow-up 
(table 3). Men in the intervention group more frequently reported their primary female 
partner's disclosure of her HIV status, and their own disclosure of HIV status (table 3). HIV 
incidence for both sexes combined was lower in the intervention group than in the control 
group after adjustment (table 4). The intervention was associated with a significantly lower 
HIV incidence in men (p=0·0304) but did not differ in women (p=0·1020; table 4).
The appendix contains a table to show secular trends in HIV incidence rates by groups for 
the RCCS population during five consecutive RCCS survey intervals between 2004 and 
2011. The first interval (2004–05) was before study initiation. At baseline (2005–06), HIV 
incidence did not significantly differ between groups (1·05 per 100 person-years). HIV 
incidence was lower in the intervention than in the control group during the intervention 
roll-out phase (2006–08), at the first follow-up interval (aIRR 0·60, 95% CI 0·42–0·84), and 
full implementation phase (2008–09) at the second follow-up interval (0·66, 0·49–0·90). 
During the scale-up and full implementation phases of the intervention (2006–09), HIV 
incidence decreased in the intervention group, compared with pre-baseline, and at follow-up 
intervals one and two. By contrast, incidence increased in the control group during these two 
follow-up intervals. However, during the post-SHARE follow-up (2010–11) incidence was 
similar between study groups, suggesting that the difference in HIV incidence between 
groups was not sustained post-intervention.
Although baseline uptake of HAART was similar between groups (table 1), more women 
than men infected with HIV were taking HAART in both the control (49 [11%] vs 17 [7%]) 
and intervention (46 [13%] vs 19 [10%]) clusters, which might have contributed to the larger 
decrease in HIV incidence in men at second follow-up. Men and women's use of HAART 
increased over the course of the trial and remained similar at final follow-up for women in 
the control group at 34% (111 of 328) versus the intervention group at 32% (72 of 227; 
p=0·6009). In men, final follow-up HAART use in the control group was 24% (46 of 193) 
versus 33% (39 of 118, p=0·0768) in the intervention group. We noted no significant 
correlation within clusters for all IPV outcomes (r=0, p=1·0) and previous research 
established low within-cluster correlation for HIV outcomes.24
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Discussion
SHARE significantly reduced reports of women's physical IPV, sexual IPV, and forced sex. 
However, male-reported perpetration of IPV was not significantly affected by the 
intervention and differences in emotional IPV were not significant. SHARE was also 
associated with significant increases in disclosure of HIV status in men and women. Finally, 
SHARE was associated with a lower HIV incidence during the intervention period, but this 
reduction was not maintained after SHARE ended, suggesting that continued exposure to the 
intervention might be need to achieve a sustained effect.
Reports of physical and sexual IPV victimisation from women were much more common 
than were reports of perpetration from men, as seen in other studies37 and consistent with 
findings from the SASA! trial in Uganda (panel 3).40 Although some of these differences 
might be because of less effective programming with men or difficulty involving men in 
SHARE activities,29 we believe that there was substantial under-reporting of IPV 
perpetration. Male under-reporting could be due to a social desirability bias and stigma 
associated with disclosing abuse37 or gender differences in patterns of reporting abusive 
behaviours.21 As in the SASA! trial,40 the discrepancy between reports of sexual violence 
between men and women were larger than were those of physical violence, possibly due to 
social norms condoning physical male disciplinary violence in Uganda.21,41 Marital rape (ie, 
forced sex) is not illegal in Uganda and choices about when to have sex are considered to be 
a man's prerogative.42 Therefore, men might have under-reported sexual violence because 
they did not perceive it to be abuse. For these reasons, we considered women's accounts of 
IPV to be the more reliable outcomes.
The intervention was associated with a lower HIV incidence in the intervention group (aIRR 
0·67 [95% CI 0·46–0·97]), which was more pronounced in men (0·59 [0·35–0·95]) than in 
women (0·72 [0·49–1·07]). Although we cannot identify the specific cause of these 
reductions, decreases in forced sex and increases in HIV disclosure might have contributed 
to reductions in HIV incidence in the intervention group.
There is a plausible biological explanation for a causal association between decreases in 
forced sex and falls in HIV infection in women. Forced, penetrative sex might induce a 
traumatic inflammatory response that recruits target cells to the vaginal or cervical site of 
injury3,43 and disrupts the integrity of the epithelial barrier, increasing susceptibility to 
HIV.3 However, the small number of women reporting forced sex in our study suggests that 
the reductions in forced sex would have only had a slight effect on female HIV incidence. 
Women who experience IPV might also have heightened susceptibility to HIV infection due 
to a clustering of their own risk behaviours and those of their violent male partner. 
Unmeasured behaviours of women (eg, anal sex, commercial sex work) and their male 
partners (eg, substance use, undisclosed sexual assault on partners and non-partners) might 
account for the decreases of HIV incidence in our study. Thus, although interpretation of the 
mechanisms by which reductions in IPV might have contributed to differences in HIV 
incidence is problematic, our results are supported by an observational study20 from Rakai 
that estimated that the adjusted population fraction of HIV attributable to IPV (emotional, 
physical, and sexual) was 22%.
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The intervention was also associated with significantly increased rates of self-disclosure and 
partner-disclosure of HIV results, which might have contributed to differences in HIV 
incidence. Increased disclosure suggests a rise in communication between partners and 
improved discussion and implementation of HIV risk reduction. Disclosure might have 
motivated more men and women, particularly in the intervention group, to seek HIV testing 
or access medical care, including HAART.
This trial coincided with the introduction of HAART and a HIV prevention trial that 
circumcised men.33 The use of HAART was higher in women than in men at baseline, 
which might have contributed to lower rates of new infections in men, but HAART was 
equitably provided to all participants and so availability of treatment should not have biased 
incidence between study groups. Although circumcision reduces male HIV acquisition,33,44 
it is unlikely to account for differences in rates for HIV acquisition in men between study 
groups since circumcision prevalence was similar at baseline and we controlled for 
circumcision status at follow-up.
Our trial has several limitations. Cluster randomisation was based on a randomisation 
scheme designed for a previous family planning cluster-randomised trial and due to financial 
constraints, we could only introduce the intervention into four of the 11 clusters, leading to 
an imbalance in numbers and poor comparability for some variables at baseline. However, 
adjustment for the covariates that differed at baseline probably minimised confounding. 
Additionally, the previous family planning intervention increased hormonal contraceptive 
use and decreased the pregnancy rate, but had no effect on condom use,28 and thus probably 
had little to no effect on the results of our study. The retention rate (75% at either follow-up 
visit) was low and differed between groups and so it is possible that selective losses to 
follow-up might have affected trial results; higher-risk individuals were more likely to 
discontinue than were those at a lower risk (data not shown). Additionally, retention rates 
were somewhat higher in the control than in the intervention group (figure 2) so selective 
loss to follow-up of higher-risk individuals in the intervention group might have 
differentially reduced HIV incidence.
Intervention group participants might have been more motivated to report lower IPV than 
were those in the control group due to a social desirability bias. However, a meta-analysis 
suggested low to moderate correlation between self-reports of IPV and validated scores of 
social desirability.45 Although contamination between groups could have occurred (eg, by 
police or community services whose jurisdictions covered both areas), we believe it is 
unlikely because RCCS clusters are geographically separated and any contamination would 
bias results towards the null.
As noted in other studies in Africa,46 reports of self-disclosure of HIV status were higher 
than were reports of partner-disclosure in both men and women, which might be due to a 
social desirability bias. Alternatively, respondents who were HIV-infected and in violent 
relationships might have feared to share their results with a partner, but falsely claim that 
they did so.46 Self-reports of HIV status disclosure might be potentially of questionable 
reliability, but reports of partner disclosure significantly increased in both men and women 
with exposure to SHARE, and might have contributed to differences in HIV incidence.
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We did not obtain data for the frequency or severity of IPV. Thus, we were not able to 
distinguish repeated abuse from isolated events, and severe and moderate forms of violence 
from minor abuse. We recommend that future research assess the severity and frequency of 
violence. As noted, we also did not measure all sexual risk behaviours that are potential 
pathways between IPV and HIV infection and thus we do not know how they might have 
contributed to decreases in HIV incidence.
In conclusion, exposure to SHARE was associated with significant decreases in both 
intimate partner violence and HIV incidence in Rakai. These findings hold great potential 
for HIV programmes and should inform future work toward universal targets for HIV 
prevention, treatment, and care. We believe our findings can be extended to other settings in 
sub-Saharan Africa and as countries in the region are scaling up combination HIV 
prevention and interventions to eliminate mother-to-child transmission of HIV, stakeholders 
should consider the potential use of investigating IPV prevention into HIV counselling and 
testing, treatment, and care services. The SHARE community mobilisation approach is a 
potential model that countries can incorporate into their national programmes and we 
recommend that it be replicated and rigorously assessed through longitudinal research to 
investigate its effect in other settings. It is also important to establish which risk behaviours 
mediate the relation between IPV and HIV infection. Finally, as international initiatives 
emphasise the importance of health strategies that promote gender equality and prioritise the 
needs of women and girls, this study's findings suggest that the SHARE model is a 
promising, gender-responsive intervention to reduce both IPV against women and infection 
with HIV.
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Panel 1: Rakai Health Sciences Program's routine HIV prevention and 
treatment services
Both groups were given Rakai Health Sciences Program's routine HIV prevention and 
treatment services, which included the following items:
• Provision of free condoms
• Syndromic sexual transmitted infection treatment
• General medical care
• Prevention of mother-to-child HIV transmission
• HIV prevention and general health education
• HIV monitoring and treatment: people with HIV who accepted voluntary 
counselling and testing were referred for free CD4 cell count assessment and 
HIV care, including co-trimoxazole prophylaxis for opportunistic diseases, 
bednets for malaria prevention, clean water containers and hypochlorite for 
prevention of diarrhoea, and positive living education
• HAART: individuals were started on standard first-line ART when they reached 
WHO stage IV disease or had a CD4 cell count of lower than 250 cells per μL; 
individuals taking HAART were monitored via CD4 cell counts and HIV viral 
lo ads
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Panel 2: Safe Homes and Respect for Everyone (SHARE) Intervention 
Structure and Strategy
Phase 1: Community assessment (2000–04)
This pre-intervention phase aimed to assess the magnitude, determinants, correlates, and 
outcomes of intimate partner violence (IPV), and to develop relationships with the 
community, hire and train SHARE staff, and prepare for intervention rollout.
Phase 2: Raising awareness (2005–06)
Intervention rollout: aimed to introduce SHARE and stimulate dialogue on IPV, help 
people to define and understand it, and raise awareness about IPV's negative 
consequences.
Phase 3: Building networks (2006–07)
Intervention scale-up aimed to prepare the community to change their attitudes about IPV 
and reduce their own violent behaviours.
Phase 4: Integrating action (2007–08)
Full intervention implementation; goal was to make actions against IPV part of everyday 
life and institutional policies and practices.
Phase 5: Consolidating efforts (2008–09)
This final, intervention wind-down phase aimed to transition SHARE staffmembers away 
from routine work in the intervention clusters while community members assumed the 
day-to-day tasks of the project. The goal was to ensure that the community could sustain 
the reduced levels of IPV through development of long-term action plans and local 
bylaws that continue prevention efforts.
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Panel 3: Research in context
Systematic review
In January, 2004, we searched PubMed, Scopus, and PsycINFO for English-language 
systematic reviews and randomised controlled trials of community-based interventions to 
reduce intimate partner violence (IPV) and HIV infection. We used a combination of text 
terms and subject headings, and open-ended search dates, but did not identify any 
reviews or trials on integrated IPV and HIV reduction efforts. A 2000 review paper 
recommended that HIV prevention programmes integrate multidisciplinary approaches to 
account for the role that violence has in women's lives.5 In response, we used a public 
health process to integrate the Safe Homes and Respect for Everyone (SHARE) violence 
reduction intervention into Rakai Health Sciences Program's (RHSP) existing HIV 
services in Uganda.29 With data from the Rakai Community Cohort Study, we estimated 
the prevalence, determinants, and correlates of IPV and HIV infection. Next, we chose 
two prevention approaches adapted to meet the needs of the population. We chose the 
Resource Guide for Mobilising Communities to Prevent Domestic Violence31 and 
Stepping Stones38 because both were developed for use in rural Africa and had been 
implemented in Uganda; both were community-based, developed for sustainability, and 
focused on change at multiple levels; and together they included strategies to address 
IPV, gender norms and inequalities, HIV, communication and relationship skills among 
adults and adolescents. We also used recommendations5 to add procedures to RHSP's 
HIV counselling and testing programmes to identify and assist women at risk of IPV. 
Reviews done in 201014 and 201339 examined interventions addressing HIV and IPV 
globally and in sub-Saharan Africa. Both highlighted the promise multifaceted 
community-based interventions hold for improving women's health and empowerment, 
but noted that although some previous interventions have reduced IPV, none have shown 
a decrease in HIV infection.14,39
Interpretation
SHARE is the first study of behavioural interventions to show significant decreases in 
both IPV and HIV incidence. As for Stepping Stones,16 IMAGE,18 and SASA!,19 
SHARE was multifaceted and done at the population-level. Uniquely, SHARE was 
nested within the infrastructure of an existing HIV research and service provision 
organisation. The SHARE intervention model could inform other HIV programmes’ 
efforts to address IPV and HIV simultaneously, and its approach could be adopted, at 
least partly, as a standard of care for other HIV programmes in sub-Saharan Africa. HIV 
counselling and testing provides an opportunity to screen for and address IPV and 
counsellors could mitigate important contextual risks factors for HIV transmission that 
are associated with experiences of violence. We also recommend5 that HIV counselling 
and testing services consider the needs of violence survivors and offer risk reduction 
counselling and disclosure support in the context of women's risk of abuse.
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Figure 1. Logic model of the SHARE Project
SHARE=Safe Homes and Respect for Everyone. IPV=intimate partner violence. 
CAC=community activism course. CCA=community counselling aides. RHSP=Rakai 
Health Sciences Program. HCT=HIV counselling and testing. ART=antiretroviral therapy.
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Figure 2. Study profile
*Four intervention clusters from the Rakai Community Cohort Study (RCCS) randomly 
chosen; two of these and five RCCS control clusters became the control populations. 
†People who could not be re-contacted were those who could not be contacted at the first 
follow-up but available at follow-up 2; those lost to follow-up were individuals who were 
not available at first follow-up and second follow-up.
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Table 1
Baseline characteristics and risk behaviours in past year
Women (n=6702) Men (n=4746)
Control (n=3544; 53%) Intervention (n=3158; 47%) p value Control (n=2567; 54%) Intervention (n=2179; 46%) p value
Age, years 0·0012 0·0343
    15-19 374 (11%) 369 (12%) .. 199 (8%) 225 (10%) ..
    20-24 887 (25%) 766 (24%) .. 484 (19%) 397 (18%) ..
    25-29 956 (27%) 755 (24%) .. 590 (23%) 474 (22%) ..
    30-34 629 (18%) 538 (17%) .. 503 (20%) 437 (20%) ..
    ≥35 698 (20%) 730 (23%) .. 791 (31%) 646 (30%) ..
Religion 0·0949 0·4802
    Christian 2948 (83%) 2621 (84%) .. 2126 (83%) 1778 (82%) ..
    Muslim 566 (16%) 481 (15%) .. 421 (16%) 371 (17%) ..
    Other or no religion 22 (1%) 34 (1%) .. 19 (1%) 22 (1%) ..
Education level 0·0425 0·0110
    None 523 (15%) 526 (17%) .. 262 (10%) 222 (10%) ..
    Primary 1981 (56%) 1769 (56%) .. 1435 (57%) 1304 (60%) ..
    Secondary or higher 1040 (30%) 863 (27%) .. 870 (34%) 653 (30%) ..
Marital status 0·5109 0·0491
    Never married 476 (13%) 456 (14%) .. 575 (22%) 528 (24%) ..
    Currently married or 
in union
2991 (84%) 2635 (83%) .. 1949 (76%) 1596 (73%) ..
    Previously married 77 (2%) 67 (2%) .. 46 (2%) 55 (3%) ..
Circumcised 
participants (if men) or 
partners (if women)
1191 (34%) 1017 (32%) 0·2612 381 (20%) 376 (22%) 0·2501
Past-year IPV
    Emotional 878 (25%) 772 (25%) 0·7574 771 (30%) 626 (29%) 0·2163
    Physical 653 (18%) 523 (17%) 0·0451 316 (12%) 242 (11%) 0·1853
    Sexual 580 (16%) 415 (13%) 0·0005 147 (6%) 92 (4%) 0·0153
Past-year forced sex 500 (14%) 357 (12%) 0·0001 101 (4%) 58 (3%) 0·0192
>1 sexual partners in 
past year
214 (6%) 157 (5%) 0·0621 1208 (47%) 914 (42%) 0·0001
Alcohol with sex (past 
year)
887 (25%) 821 (26%) 0·3654 943 (39%) 876 (40%) 0·2019
Number non-marital 
sex partners in past 
year
0·0561 0·0001
    0 2516 (82%) 2268 (84%) .. 1378 (54%) 1280 (59%) ..
    1 483 (16%) 392 (15%) .. 800 (31%) 608 (28%) ..
    ≥2 69 (2%) 42 (2%) .. 389 (15%) 291 (13%) ..
Condom use in past 
year
0·7330 0·0911
    Yes, always 316 (9%) 274 (9%) .. 398 (16%) 378 (17%) ..
    None or inconsistent 3228 (91%) 2884 (91%) .. 2169 (85%) 1801 (83%) ..
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Women (n=6702) Men (n=4746)
Control (n=3544; 53%) Intervention (n=3158; 47%) p value Control (n=2567; 54%) Intervention (n=2179; 46%) p value
Partner's disclosure of 
HIV status (past year)
669 (19%) 481 (15%) 0·0001 544 (22%) 365 (17%) 0·0001
Self-disclosure of HIV 
status to partner (past 
year)
949 (27%) 764 (24%) 0·0210 647 (26%) 411 (19%) 0·0001
    HIV prevalence* 448/3175 (14%) 343/2814 (12%) 0·0026 253/2896 (11%) 184/2789 (9%) 0·0288
    HAART uptake* 49/448 (11%) 46/343 (13%) 0·2888 17/253 (7%) 19/184 (10%) 0·1758
Data are n (%), unless otherwise indicated.
*
Population size differs due to availability of blood samples.
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Table 2
Effect of intervention on IPV outcomes
Control Intervention PRR (95% CI)
aPRR*(95% CI)
Women
Experience of past-year emotional (verbal) abuse
    Follow-up 1 498/2338 (21%) 495/2257 (22%) 1·03 (0·92-1·15) 1·02 (0·92-1·14)
    Follow-up 2 409/2039 (20%) 311/1737 (18%) 0·89 (0·78-1·02) 0·91 (0·79-1·04)
Experience of past-year physical IPV
    Follow-up 1 397/2426 (16%) 353/2342 (15%) 0·92 (0·81-1·05) 0·97 (0·85-1·11)
    Follow-up 2 346/2127 (16%) 217/1812 (12%) 0·74 (0·63-0·86) 0·79 (0·67-0·92)
Experience of past-year sexual IPV
    Follow-up 1 292/2337 (13%) 296/2257 (13%) 1·05 (0·90-1·22) 1·12 (0·96-1·31)
    Follow-up 2 261/2038 (13%) 167/1737 (10%) 0·75 (0·62-0·90) 0·80 (0·67-0·97)
Experience of past-year forced sex
    Follow-up 1 261/2337 (11%) 262/2257 (12%) 1·04 (0·88-1·22) 1·12 (0·95-1·32)
    Follow-up 2 232/2038 (11%) 145/1737 (8%) 0·73 (0·60-0·89) 0·79 (0·65-0·96)
Men
Perpetration of past-year emotional (verbal) IPV
    Follow-up 1 520/1586 (33%) 401/1367 (29%) 0·92 (0·80-0·99) 0·88 (0·78-0·98)
    Follow-up 2 315/1407 (22%) 251/1104 (23%) 1·02 (0·88-1·18) 0·99 (0·85-1·16)
Perpetration of past-year physical IPV
    Follow-up 1 185/1641 (11%) 132/1433 (9%) 0·82 (0·66-1·01) 0·80 (0·64-1·00)
    Follow-up 2 124/1437 (9%) 99/1150 (9%) 1·00 (0·77-1·28) 1·00 (0·77-1·30)
Perpetration of past-year sexual IPV
    Follow-up 1 73/1586 (5%) 56/1367 (4%) 0·89 (0·63-1·25) 0·90 (0·63-1·28)
    Follow-up 2 53/1407 (4%) 30/1104 (3%) 0·72 (0·46-1·12) 0·81 (0·52-1·26)
Perpetration of past-year forced sex
    Follow-up 1 47/1586 (3%) 38/1367 (3%) 0·94 (0·61-1·43) 1·00 (0·65-1·55)
    Follow-up 2 39/1407 (3%) 24/1104 (2%) 0·78 (0·47-1·30) 0·85 (0·50-1·42)
Data are n/number who responded (%) unless otherwise stated. IPV=intimate partner violence. PRR=prevalence rate ratio. aPRR=adjusted 
prevalence rate ratio.
*
Effects of intervention adjusted for baseline age, baseline education, baseline marital status, and baseline experience of IPV victimisation 
(women) or perpetration (men), according to type measured.
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Table 3
Effect of intervention on risk behaviours and HIV disclosure
Control Intervention PRR (95% CI)
aPRR* (95% CI)
Women
>1 sexual partners in past year
    Follow-up 1 214/2426 (9%) 201/2341 (9%) 1·00 (0·98-1·01) 1·00 (0·98-1·01)
    Follow-up 2 207/2127 (10%) 157/1812 (9%) 0·99 (0·97-1·01) 0·98 (0·97-1·00)
Non-marital sex partners in past year
    Follow-up 1 377/2224 (17%) 367/2127 (17%) 1·02 (0·89-1·16) 1·01 (0·90-1·15)
    Follow-up 2 396/2006 (20%) 306/1693 (18%) 0·92 (0·80-1·05) 0·89 (0·78-1·01)
Alcohol use with sex in past year
    Follow-up 1 647/2426 (27%) 620/2342 (27%) 0·99 (0·90-1·09) 0·99 (0·91-1·09)
    Follow-up 2 435/2127 (21%) 361/1812 (20%) 0·97 (0·86-1·10) 0·96 (0·85-1·09)
Condom use in past year
    Follow-up 1 201/2362 (9%) 216/2282 (10%) 1·11 (0·93-1·34) 1·12 (0·95-1·33)
    Follow-up 2 192/1170 (16%) 157/931 (17%) 1·03 (0·85-1·25) 1·01 (0·84-1·21)
Partner's disclosure of HIV status in past year
    Follow-up 1 497/2340 (21%) 492/2257 (22%) 1·03 (0·92-1·15) 1·03 (0·92-1·15)
    Follow-up 2 455/2037 (22%) 457/1740 (26%) 1·18 (1·05-1·32) 1·18 (1·06-1·32)
Self-disclosure of HIV status to partner in past year
    Follow-up 1 874/2339 (37%) 880/2257 (39%) 1·04 (0·97-1·12) 1·05 (0·97-1·12)
    Follow-up 2 752/2036 (37%) 731/1740 (42%) 1·14 (1·05-1·23) 1·15 (1·06-1·24)
Men
>1 sexual partners in past year
    Follow-up 1 829/1612 (51%) 668/1406 (48%) 0·92 (0·90-0·99) 0·96 (0·90-1·03)
    Follow-up 2 676/1437 (47%) 538/1150 (47%) 0·99 (0·91-1·08) 1·02 (0·94-1·10)
Non-marital sex partners in past year
    Follow-up 1 804/1641 (49%) 642/1433 (45%) 0·91 (0·85-0·99) 0·95 (0·89-1·02)
    Follow-up 2 645/1437 (45%) 495/1150 (43%) 0·96 (0·88-1·05) 0·98 (0·90-1·06)
Alcohol use with sex (past year)
    Follow-up 1 787/1612 (49%) 697/1406 (50%) 1·02 (0·94-1·09) 1·03 (0·97-1·09)
    Follow-up 2 670/1437 (47%) 525/1150 (46%) 0·98 (0·90-1·06) 0·98 (0·91-1·05)
Condom use in past year
    Follow-up 1 217/1613 (14%) 216/1408 (15%) 1·14 (0·96-1·36) 1·06 (0·90-1·24)
    Follow-up 2 188/806 (23%) 153/601 (26%) 1·09 (0·91-1·31) 1·04 (0·87-1·24)
Partner's disclosure of HIV status in past year
    Follow-up 1 425/1607 (27%) 372/1374 (27%) 1·02 (0·91-1·15) 1·09 (0·97-1·22)
    Follow-up 2 401/1409 (29%) 385/1107 (35%) 1·22 (1·09-1·37) 1·24 (1·11-1·39)
Self-disclosure of HIV status to partner in past year
    Follow-up 1 549/1607 (34%) 494/1374 (36%) 1·05 (0·95-1·16) 1·10 (1·00-1·21)
    Follow-up 2 444/1409 (32%) 404/1107 (37%) 1·16 (1·04-1·29) 1·17 (1·05-1·31)
All data are n/number who responded (%), unless otherwise indicated. PRR=prevalence rate ratio. aPRR=adjusted prevalence rate ratio.
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*
Effects of intervention adjusted for baseline age, baseline education, baseline marital status and baseline number of non-marital sex partners. Each 
outcome was also adjusted for its baseline measure.
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